Deals and M&A

In the coronavirus fight, Vir and Alnylam expand RNAi agreement

March 4, 2020

Vir Biotechnology Inc. and Alnylam Pharmaceuticals Inc. are expanding an infectious disease collaboration begun three years ago to take on the coronavirus. The effort now includes developing and commercializing RNAi therapies targeting SARS-CoV-2, the virus that triggers COVID-19, by developing siRNAs identified by Alnylam.

Thermo Fisher to buy molecular diagnostics company Qiagen for $11.5B

March 3, 2020

By Liz Hollis

No Comments

Thermo Fisher Scientific Inc., of Waltham, Mass., has made a bold play in the molecular diagnostics market, including infectious disease testing, with its proposed $11.5 billion acquisition of Qiagen NV, of Venlo, Netherlands. Word of the deal comes after reports late last year that named Thermo Fisher as a potential suitor for Qiagen. However, in late December, Qiagen said it had wrapped up a review of potential strategic alternatives and decided its standalone business plan represented the best opportunity for value creation.

Abpro further commits to Asia in $1.1B bispecific deal

March 3, 2020

By Lee Landenberger

No Comments

Abpro Therapeutics Inc. has granted an exclusive license to Abpro Bio Co. Ltd., the former Ugint Co. Ltd., to develop and commercialize two bispecific antibodies in Asian markets, including greater China, Japan and South Korea.

Gilead grows its immuno-oncology portfolio with $4.9B acquisition of Forty Seven

March 2, 2020

By Lee Landenberger

No Comments

Gilead Sciences Inc. will acquire Forty Seven Inc. for $4.9 billion, or $95.50 per share in cash, bringing Gilead magrolimab, an anti-CD47 monoclonal antibody being developed to treat several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).

Biocom Global Life Sciences Partnering Conference

Pharmas share their needs, wants and offer some advice

March 2, 2020

By Brian Orelli

No Comments

SAN DIEGO – At the Biocom 10th Annual Global Life Sciences Partnering Conference, panels of pharma executives highlighted what they're looking for to supplement their pipelines and offered advice that ran the gamut from company formation to the courting process to strategies for partnering pipeline drugs and platforms.

Biogen inks $2.7B+ deal with Sangamo targeting neurological diseases

February 28, 2020

By Michael Fitzhugh

No Comments

Launching a broad new front in its long-running battle against dementia and other neurological diseases, Biogen Inc. has moved to license multiple Sangamo Therapeutics Inc. programs for $350 million up front plus up to $2.37 billion in development, regulatory and commercial milestone payments.

From Ixinity and beyond: Buzz for Aptevo as bispecific pure play ‘cleaner’

February 28, 2020

By Randy Osborne

No Comments

Aptevo Therapeutics Inc.’s chief scientific officer, Jane Gross, told BioWorld that the sale of the firm’s marketed recombinant hemophilia B therapeutic, Ixinity, to Medexus Pharmaceuticals Inc. allowed for a “cleaner message” to Wall Street. “It was a little difficult to explain having a commercial asset and an R&D pipeline,” she said.

2-28-Fuzionaire-Montreal Siemens-ECAT.png

Fuzionaire, Canadian researchers shine light on neurodegenerative diseases

February 28, 2020

By David Godkin

No Comments

TORONTO – Montreal’s McGill University and the Montreal Neurological Institute-Hospital (The Neuro) have entered a research agreement with Pasadena, Calif.-based Fuzionaire Diagnostics Inc. to detect and treat neurodegenerative diseases through molecular imaging.

Biogen inks $2.7B+ deal with Sangamo targeting neurological diseases

February 27, 2020

By Michael Fitzhugh

No Comments

Livanova teams up with Verily on depression trial

February 27, 2020

By Meg Bryant

No Comments

London-based Livanova plc has entered a collaboration with Verily Inc., an Alphabet company, to enrich data from its RECOVER trial using tools and analytics developed by Verily. The study, which kicked off last September, is assessing the effectiveness of vagus nerve stimulation (VNS) therapy for patients with difficult-to-treat depression (DTD).

Deals and M&A
RSS

In the coronavirus fight, Vir and Alnylam expand RNAi agreement

Thermo Fisher to buy molecular diagnostics company Qiagen for $11.5B

Abpro further commits to Asia in $1.1B bispecific deal

Gilead grows its immuno-oncology portfolio with $4.9B acquisition of Forty Seven

Pharmas share their needs, wants and offer some advice

Biogen inks $2.7B+ deal with Sangamo targeting neurological diseases

From Ixinity and beyond: Buzz for Aptevo as bispecific pure play ‘cleaner’

Fuzionaire, Canadian researchers shine light on neurodegenerative diseases

Biogen inks $2.7B+ deal with Sangamo targeting neurological diseases

Livanova teams up with Verily on depression trial

Popular Stories

South Korea approves first four COVID-19 test kits under urgent-use license

CHF Solutions looks to bring its tech to help COVID-19 patients

Sihuan starts clinical trial of Ebola drug favipiravir for COVID-19

Mallinckrodt to submit IND to FDA for inhaled nitric oxide to treat COVID-19 respiratory distress

Two South Korean COVID-19 kits look overseas, seek FDA approval

BioWorld Premium

Deals and M&A RSS

Popular Stories

BioWorld Premium

Deals and M&A
RSS